Ipsen granted EU nod for Exelixis-partnered cancer drug for neuroendocrine tumors
Source: SeekingAlpha
2025-07-24 14:10:46 ET
More on Exelixis, Ipsen
- Exelixis: I Was Wrong To Be Too Cautious (Rating Upgrade)
- Exelixis: Zanzalintinib MOA Overcomes Competing CRC Regorafenib Treatment
- Exelixis: A Notable Quarter
- Exelixis cut to sector perform at RBC as cash flows fairly valued
- Exelixis jumps on phase 3 data for zanzalintinib in colorectal cancer
Read the full article on Seeking Alpha
For further details see:
Ipsen granted EU nod for Exelixis-partnered cancer drug for neuroendocrine tumors
Exelixis Inc.
NASDAQ: EXEL
EXEL Trading
0.07% G/L:
$40.86 Last:
740,799 Volume:
$41.665 Open:
EXEL Latest News
February 28, 2026 04:57:00 am
3 Reasons Exelixis Stock Could Deliver Market?Beating Returns Over the Next Decade
February 24, 2026 04:05:00 pm
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March
February 24, 2026 10:58:00 am
Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge
February 20, 2026 04:05:00 pm
Exelixis: The Cash?Generating Biotech That I Think Deserves a Closer Look in 2026
EXEL Stock Data
$11,614,618,641
260,551,394
1.54%
313
N/A
Biotechnology & Life Sciences
Healthcare
US
Alameda
